310 related articles for article (PubMed ID: 18312458)
1. Elevation of IgG levels is a serological indicator for pulmonary fibrosis in systemic sclerosis with anti-topoisomerase I antibodies and those with anticentromere antibody.
Komura K; Yanaba K; Ogawa F; Shimizu K; Takehara K; Sato S
Clin Exp Dermatol; 2008 May; 33(3):329-32. PubMed ID: 18312458
[TBL] [Abstract][Full Text] [Related]
2. Anti-agalactosyl IgG antibodies in sera from patients with systemic sclerosis.
Nishijima C; Sato S; Takehara K
J Rheumatol; 2001 Aug; 28(8):1847-51. PubMed ID: 11508588
[TBL] [Abstract][Full Text] [Related]
3. Anti-DNA topoisomerase II alpha autoantibodies in Japanese patients with systemic sclerosis.
Hayakawa I; Hasegawa M; Takehara K; Sato S
Arch Dermatol Res; 2005 Oct; 297(4):180-3. PubMed ID: 16180014
[TBL] [Abstract][Full Text] [Related]
4. Serum pulmonary and activation-regulated chemokine/CCL18 levels in patients with systemic sclerosis: a sensitive indicator of active pulmonary fibrosis.
Kodera M; Hasegawa M; Komura K; Yanaba K; Takehara K; Sato S
Arthritis Rheum; 2005 Sep; 52(9):2889-96. PubMed ID: 16142750
[TBL] [Abstract][Full Text] [Related]
5. Clinical and serological heterogeneity in patients with anticentromere antibodies.
Miyawaki S; Asanuma H; Nishiyama S; Yoshinaga Y
J Rheumatol; 2005 Aug; 32(8):1488-94. PubMed ID: 16078324
[TBL] [Abstract][Full Text] [Related]
6. Juvenile systemic sclerosis: report of three cases and review of Japanese published work.
Aoyama K; Nagai Y; Endo Y; Ishikawa O
J Dermatol; 2007 Sep; 34(9):658-61. PubMed ID: 17727371
[TBL] [Abstract][Full Text] [Related]
7. Clinical significance of surfactant protein D as a serum marker for evaluating pulmonary fibrosis in patients with systemic sclerosis.
Asano Y; Ihn H; Yamane K; Yazawa N; Kubo M; Fujimoto M; Tamaki K
Arthritis Rheum; 2001 Jun; 44(6):1363-9. PubMed ID: 11407696
[TBL] [Abstract][Full Text] [Related]
8. Rheumatoid factor isotypes and anti-agalactosyl IgG antibodies in systemic sclerosis.
Mimura Y; Ihn H; Jinnin M; Asano Y; Yamane K; Yazawa N; Tamaki K
Br J Dermatol; 2004 Oct; 151(4):803-8. PubMed ID: 15491420
[TBL] [Abstract][Full Text] [Related]
9. Autoantibody profiles in systemic sclerosis: predictive value for clinical evaluation and prognosis.
Hamaguchi Y
J Dermatol; 2010 Jan; 37(1):42-53. PubMed ID: 20175839
[TBL] [Abstract][Full Text] [Related]
10. Pulmonary arterial hypertension and severe pulmonary fibrosis in systemic sclerosis patients with a nucleolar antibody.
Steen VD; Lucas M; Fertig N; Medsger TA
J Rheumatol; 2007 Nov; 34(11):2230-5. PubMed ID: 17937469
[TBL] [Abstract][Full Text] [Related]
11. Autoantibody against peroxiredoxin I, an antioxidant enzyme, in patients with systemic sclerosis: possible association with oxidative stress.
Iwata Y; Ogawa F; Komura K; Muroi E; Hara T; Shimizu K; Hasegawa M; Fujimoto M; Tomita Y; Sato S
Rheumatology (Oxford); 2007 May; 46(5):790-5. PubMed ID: 17309887
[TBL] [Abstract][Full Text] [Related]
12. Elevated serum concentrations of polymorphonuclear neutrophilic leukocyte elastase in systemic sclerosis: association with pulmonary fibrosis.
Hara T; Ogawa F; Yanaba K; Iwata Y; Muroi E; Komura K; Takenaka M; Shimizu K; Hasegawa M; Fujimoto M; Sato S
J Rheumatol; 2009 Jan; 36(1):99-105. PubMed ID: 19208531
[TBL] [Abstract][Full Text] [Related]
13. Serum levels of monocyte chemotactic protein-3/CCL7 are raised in patients with systemic sclerosis: association with extent of skin sclerosis and severity of pulmonary fibrosis.
Yanaba K; Komura K; Kodera M; Matsushita T; Hasegawa M; Takehara K; Sato S
Ann Rheum Dis; 2006 Jan; 65(1):124-6. PubMed ID: 16344498
[TBL] [Abstract][Full Text] [Related]
14. Correlation of serum anti-DNA topoisomerase I antibody levels with disease severity and activity in systemic sclerosis.
Hu PQ; Fertig N; Medsger TA; Wright TM
Arthritis Rheum; 2003 May; 48(5):1363-73. PubMed ID: 12746909
[TBL] [Abstract][Full Text] [Related]
15. Clinical subsets, skin thickness progression rate, and serum antibody levels in systemic sclerosis patients with anti-topoisomerase I antibody.
Perera A; Fertig N; Lucas M; Rodriguez-Reyna TS; Hu P; Steen VD; Medsger TA
Arthritis Rheum; 2007 Aug; 56(8):2740-6. PubMed ID: 17665460
[TBL] [Abstract][Full Text] [Related]
16. Serum levels of KL-6 as a useful marker for evaluating pulmonary fibrosis in patients with systemic sclerosis.
Yamane K; Ihn H; Kubo M; Yazawa N; Kikuchi K; Soma Y; Tamaki K
J Rheumatol; 2000 Apr; 27(4):930-4. PubMed ID: 10782818
[TBL] [Abstract][Full Text] [Related]
17. A case of systemic sclerosis with anticentromere, antitopoisomerase I, and anti-U1RNP antibodies.
Sato S; Ihn H; Soma Y; Shimozuma M; Shishiba T; Takehara K
J Rheumatol; 1993 Nov; 20(11):1961-3. PubMed ID: 8308786
[TBL] [Abstract][Full Text] [Related]
18. Serum levels of interleukin 6 (IL-6), oncostatin M, soluble IL-6 receptor, and soluble gp130 in patients with systemic sclerosis.
Hasegawa M; Sato S; Fujimoto M; Ihn H; Kikuchi K; Takehara K
J Rheumatol; 1998 Feb; 25(2):308-13. PubMed ID: 9489824
[TBL] [Abstract][Full Text] [Related]
19. IgG reactivity with a 100-kDa tissue and endothelial cell antigen identified as topoisomerase 1 distinguishes between limited and diffuse systemic sclerosis patients.
García de la Peña-Lefebvre P; Chanseaud Y; Tamby MC; Reinbolt J; Batteux F; Allanore Y; Kahan A; Meyer O; Benveniste O; Boyer O; Guillevin L; Boissier MC; Mouthon L
Clin Immunol; 2004 Jun; 111(3):241-51. PubMed ID: 15183145
[TBL] [Abstract][Full Text] [Related]
20. [Pulmonary manifestation of progressive systemic scleroderma: prognostic value of centromere antibodies and antibodies to Scl-70 nucleoprotein].
Behr J; König G; Meurer M; Krieg T
Pneumologie; 1990 Jun; 44(6):822-5. PubMed ID: 2381889
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
